In addition, a very recent report suggests that baclofen, a clinically available GABABR agonist, can ameliorate cerebellar dysfunction by enhancing mGluR1 signaling in a SCA1 model mouse line81. The gene discussed is GRM1; the disease is spinocerebellar ataxia type 1.